top of page
Venus Remedies secures exclusive in-licensing rights from Infex Therapeutics to develop and commercialise MET-X in India
Venus Remedies will commence with a Phase I trial involving volunteers in India. MET-X is Infex Therapeutics’ broad spectrum MBL-inhibitors.
Feb 254 min read
bottom of page